SynthesisThe Cochrane database of systematic reviews2012
Calcium antagonists for acute ischemic stroke.
Synthesis in The Cochrane database of systematic reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Calcium antagonists for acute ischemic stroke.The Cochrane database of systematic reviews · 2019Pooled it
- Interventions for deliberately altering blood pressure in acute stroke.The Cochrane database of systematic reviews · 2014Pooled it
- The Protective Effects of Hydrogen Sulfide New Donor MethylMolecules (Basel, Switzerland) · 2022Article
- Cerebral Autoregulation in Subarachnoid Hemorrhage.Frontiers in neurology · 2021Review
- Biomechanics and hemodynamics of stent-retrievers.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020Review
- L-type CaScience signaling · 2020Article
- Nimodipine Reappraised: An Old Drug With a Future.Current neuropharmacology · 2020Review
- Pre-clinical to Clinical Translational Failures and Current Status of Clinical Trials in Stroke Therapy: A Brief Review.Current neuropharmacology · 2020Review
- Diltiazem Promotes Regenerative Axon Growth.Molecular neurobiology · 2019Article
- An introduction to the pathophysiology of aneurysmal subarachnoid hemorrhage.Neurosurgical review · 2018Review
- The Function of the Mitochondrial Calcium Uniporter in Neurodegenerative Disorders.International journal of molecular sciences · 2017Review
- Panax notoginseng saponins administration modulates pro- /anti-inflammatory factor expression and improves neurologic outcome following permanent MCAO in rats.Metabolic brain disease · 2017Article
- Ginkgolides and bilobalide protect BV2 microglia cells against OGD/reoxygenation injury by inhibiting TLR2/4 signaling pathways.Cell stress & chaperones · 2016Article
- False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review.BMJ open · 2016Review
- Computer modeling of ischemic stroke.Drug discovery today. Disease models · 2016Article
- Ischemic conditioning-induced endogenous brain protection: Applications pre-, per- or post-stroke.Experimental neurology · 2015Review
- Impact of preadmission treatment with calcium channel blockers or beta blockers on short-term mortality after stroke: a nationwide cohort study.BMC neurology · 2015Article
- Inductive and Deductive Approaches to Acute Cell Injury.International scholarly research notices · 2014Review
- The changing landscape of voltage-gated calcium channels in neurovascular disorders and in neurodegenerative diseases.Current neuropharmacology · 2013Article
- Calcium and potassium channels in experimental subarachnoid hemorrhage and transient global ischemia.Stroke research and treatment · 2012Article
Corrections and comments
- Commented on by
- Updated by
- Update of
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe sudden loss of blood supply in ischemic stroke is associated with the increase of calcium ions within neurons. Inhibiting this increase could protect neurons and hence might reduce neurological impairment, disability and handicap after stroke.
objectivesTo determine whether calcium antagonists reduce the risk of death or dependency after acute ischemic stroke. To investigate the influence of different drugs, dosages, routes of administration, time intervals after stroke and trial design on the risk of a primary outcome. SEARCH
methodsWe searched the Cochrane Stroke Group Trials Register (January 2012), MEDLINE (1950 to December 2011), EMBASE (1980 to December 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2011 issue 4) and four Chinese databases (December 2011): Chinese Biological Medicine Database (CBM-disc), China National Knowledge Infrastructure (CNKI), Chinese scientific periodical database of VIP information and Wanfang Data. We also contacted trialists and researchers. SELECTION CRITERIA: All truly randomized trials comparing a calcium antagonist with control in patients with acute ischemic stroke. DATA COLLECTION AND ANALYSIS: Two authors assessed all trials and extracted the data. We used death or dependency at the end of long-term follow-up (at least three months) in activities of daily living as the primary outcome. Analyses were, if possible, intention-to-treat. MAIN
resultsWe included 34 trials including 7731 patients. There was no effect of calcium antagonists on the primary outcome (risk ratio (RR) 1.05; 95% confidence interval (CI) 0.98 to 1.13), or on death at the end of follow-up (RR 1.07, 95% CI 0.98 to 1.17). Comparisons of different doses of nimodipine suggested that the highest doses were associated with poorer outcome. AUTHORS'
conclusionsNo evidence is available using calcium antagonists in patients with acute ischemic stroke is effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.